AM-Pharma is developing a treatment for acute kidney injury (AKI) that could be life saving.
AM-Pharma is a clinical stage biopharmaceutical company, leading in the development of a treatment for AKI with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP). AKI is a devastating disease with high mortality rate that affects millions of patients worldwide. There is no approved pharmacological treatment for AKI and our biologic, recAP, has the potential to be a first-in-class medicine.
In addition to our lead AKI program, we have also explored the development of recAP as a potential treatment option for other indications including Inflammatory Bowel Disease (IBD) and Hypophosphatasia (HPP).